Similarly, bicistronic CD19/CD22 CAR-T cells in pediatric leukemia showed no severe CRS or neurotoxicity, suggesting that dual targeting can maintain anti-tumor efficacy while curbing inflammatory overload [54]. This evidence concerns the gene CD22 and neoplasm.